Entrada Therapeutics plans to initiate ELEVATE-44-201 trial for ENTR-601-44 in Duchenne muscular dystrophy by Q2 2025. Entrada Therapeutics, Inc. announced that it has received regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback